We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Smart Intraocular Lens Inserted into the Eye Detects Biomarkers for Alzheimer's

By LabMedica International staff writers
Posted on 13 Jan 2023
Print article
Image: Lens used in the development of smart intraocular lenses (Photo courtesy of KIMM)
Image: Lens used in the development of smart intraocular lenses (Photo courtesy of KIMM)

Scientists have developed a smart intraocular lens that can be inserted into the eye to detect biomarkers for Alzheimer's, a degenerative brain disease, and could facilitate early diagnosis of various other neurological diseases.

The smart intraocular lens that can be inserted into the eye to diagnose Alzheimer's has been developed for the first time in Korea by scientists at The Korea Institute of Machinery and Materials (KIMM, Daejeon, Korea). The intraocular implant can diagnose Alzheimer's in its early stages. The scientists developed the implantable biosensing system by mounting a bioresponsive hydrogel-based sensing module that can detect various biomarkers on an intraocular lens to express a signal in a moiré pattern.

The hydrogel pattern, to which the antibody is bound, contracts when it reacts with the target biomarker which is then detected using changes in the moiré signal. These changes are generated when the hydrogel pattern, which becomes narrower by the contraction response, overlaps with the designated reference grid. The use of a moiré signal makes detection possible with much greater sensitivity as compared to other methods that directly detect change in the hydrogel pattern.

In addition, unlike traditional biosensors, the moiré signal-based biomarker detection method is capable of directly detecting biomarkers without the use of electrochemical or fluorescent labels. This method eliminates the requirement for external power or a light source, allowing it to be implanted within the body. The scientists consider the development of this technology to be significant as it can minimize social costs by diagnosing neurological diseases, including dementia, which is common and results in social issues.

Related Links:
KIMM 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more